Enveric Biosciences, Inc.
ENVB
$1.64
$0.042.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.63% | 8.38% | 1.26% | 6.15% | 38.27% |
| Total Depreciation and Amortization | -52.84% | -40.47% | -28.16% | -17.75% | -12.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -64.22% | -62.49% | -45.25% | -9.18% | -39.01% |
| Change in Net Operating Assets | -69.71% | 30.07% | 143.95% | 195.49% | -280.97% |
| Cash from Operations | -6.48% | -5.38% | 6.09% | 34.66% | 34.93% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.55% | 74.84% | 50.43% | 16.84% | 10.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -101.40% | -106.83% | -115.31% |
| Cash from Financing | 58.00% | 37.87% | 18.93% | -8.16% | 2.81% |
| Foreign Exchange rate Adjustments | -89.55% | -128.30% | -194.07% | -728.57% | -137.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 129.80% | 5,284.04% | 155.93% | 81.76% | 66.78% |